Nu-Med Plus, Inc. announces trading on OTCQB Marketplace

Print
| Source: Nu-Med Plus Inc.

SALT LAKE CITY, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCBB:NUMD), a medical device development company announced it has begun to have its securities designated and traded as OTCQB securities which will be subject to QTCB Standards. The OTCQB market offers well informed and extremely efficient trading for companies and investors. OTCQB ensures that investors have the information necessary to intelligently analyze, value and trade their securities. OTC markets are more cost-efficient than traditional stock exchanges permitting investors to buy into companies that may well shape the world on a more cost-efficient platform.

Nitric Oxide (NO) is an essential biological gas which is currently being used for congenital pulmonary hypoplasia and neonatal hypoxia therapy. Contemporary research is being done for additional applications involving the therapeutic need for vasodilation and increased delivery of oxygen to diseased and injured tissues. The emphasis is to generate controlled-flow of INO for internal therapies with integrating accessories for availability in emergency rooms and urgent care facilities, medical and chiropractic offices, convalescent and nursing homes, and for emergency response teams for treatment of various trauma injuries.

Jeff Robins, President and CEO of Nu-Med Plus, Inc. commented, “We are very excited about the opportunity to trade our securities on the QTQB platform which will allow Nu-Med to distribute its information and bring transparency to a wide audience of U.S. investors, market data distributors, investment databases, media outlets, and broker-dealers, while allowing our investors to propel our vision forward turning our Medical Devices into technological reality.”

About Nu-Med Plus, Inc.

Nu-Med Plus, Inc. designs, develops and markets innovative medical devices for use in patient treatment. Initial research and product development has been in the delivery of nitric oxide gas for therapeutic use. For more information please visit www.nu-medplus.com.

Forward-Looking Statements
Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward looking statements are inherently uncertain and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.

Contact:
Jeff Robins
President
801-746-3570